JAMA Surg:NIRAF用于甲状腺全切除术中甲状旁腺的识别

2019-11-12 MedSci MedSci原创

在甲状腺全切除术中,使用NIRAF来识别甲状旁腺可有助于甲状旁腺的保存,降低早期术后低钙血症风险。

甲状旁腺的意外损伤会导致术后低血钙,因此在甲状腺全切除术中,鉴别和保存甲状旁腺是一项具有挑战性的工作。近日研究人员探讨术中应用近红外自荧光(NIRAF)成像系统对甲状旁腺的识别是否能改善甲状旁腺的保存,减少术后低钙血症的发生。

准备接受甲状腺全切除术的成人患者参与研究,患者术中接受NIRAF成像。研究的主要结局为术后低钙血症(在术后第1或2天经校正的钙<8.0mg/dL)的发生率。次要终点是甲状旁腺自体移植和非故意甲状旁腺切除术的发生率。

241名患者参与研究,平均年龄53.6岁,女性191例(79.3%),其中接受NIRAF辅助甲状腺切除术121例,常规甲状腺切除术120例(对照组)。NIRAF组术后暂时性低钙血症发生率为9.1%(11/121),对照组为21.7%(26/120)(组间差异为12.6%)。组间永久性低钙血症发生率无显著差异(NIRAF组为0%,对照组为1.6%,120例中2例)。多因素分析以及调整后发现使用NIRAF可降低低钙血症的风险,优势比为0.3。次要结果分析显示,NIRAF组发生甲状旁腺自体移植的患者比对照组少:分别为4例(3.3%)vs 16例(13.3%)。NIRAF组因疏忽切除甲状旁腺的数目明显低于对照组:3例(2.5%) vs14例(11.7%)。

在甲状腺全切除术中,使用NIRAF来识别甲状旁腺可有助于甲状旁腺的保存,降低早期术后低钙血症风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2023-05-05 74252_9153 来自内蒙古

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2130268, encodeId=ea14213026816, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10536197425, createdName=74252_9153, createdTime=Fri May 05 15:35:38 CST 2023, time=2023-05-05, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=1877217, encodeId=d51518e72177e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Wed Dec 04 09:34:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375418, encodeId=42523e541822, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:48 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375417, encodeId=49223e54175c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:46 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375416, encodeId=50df3e541652, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:44 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375415, encodeId=39cd3e54155c, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:40 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375414, encodeId=47a23e54146f, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:37 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375413, encodeId=3b023e54139d, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:24:34 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452478, encodeId=de2814524e844, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Thu Nov 14 10:34:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]

相关资讯

原发性甲状旁腺功能亢进:易被忽视的临床表现

76岁男性,因 “进行性四肢麻木无力2周”入院。患者家属代诉其睡眠明显增多,睡眠时难以唤醒,在外院按 “周围神经病变”治疗无好转。经入院检查最终诊断为:1.原发性甲状旁腺功能亢进并多发性周围神经病;2.泌尿系结石。该患者外院漏诊的主要原因是什么?

血糖为“0”,真相竟然是这样的!

男性患者,62岁,因“咳嗽、咯痰4+年,加重伴呼吸困难、心累气紧1+月”入院。上述症状反复发作,于院外诊断为:

甲状腺及甲状旁腺术中喉上神经外支保护与监测专家共识(2017版)

为术中快速识别EBSLN、保全功能,保障病人术后嗓音清晰、音域健全,进一步推动我国甲状腺术中神经电生理技术的临床应用和科学研究,助力中国甲状腺外科事业的发展,由中国医师协会外科医师分会甲状腺外科医师委员会(Chinese Thyroid Association,CTA)、中国研究型医院学会甲状腺疾病专业委员会神经监测学组(Chinese Neural Monitoring Study Group,

Br J Surg:甲状腺全切术中ICG造影对甲状旁腺功能的预测

术后甲状旁腺功能减退症是甲状腺术后最常见的并发症。本试验研究的目的是评估术中甲状旁腺造影术对术后甲状旁腺功能预测情况。对甲状腺全切术患者使用荧光染料吲哚菁绿(ICG)进行造影,使甲状旁腺的血管可视化。研究中共有36名患者在甲状腺全切术中进行了ICG造影,所有参与者使用钙和维生素D补充剂。有30名患者在ICG造影后可见到至少一条的甲状旁腺血管。术后第一天和第10天,这30名患者中除了1人外,其余的甲

J Am Med Assoc:甲状旁腺术前4D-CTs与术中所见不一致是为何?

甲状旁腺四维计算机断层扫描(4D-CTs)已经成为原发性甲状旁腺功能亢进患者的一项准确和具有成本效益的初步定位检查。然而,影响术前4D-CTs准确性的潜在局限性和影响因素尚不清楚。

J Clin Endocrinol Metab:术后甲状旁腺功能减退患者:靠激素治疗能改善生活质量?

2018年1月,发表在《J Clin Endocrinol Metab》的一项由意大利科学家进行的前瞻性开放标签研究,考察了甲状旁腺激素(PTH)(1-34)治疗术后甲状旁腺功能减退的有效性和安全性并调查了这些患者的生活质量(QOL)。